XML 53 R37.htm IDEA: XBRL DOCUMENT
v3.21.1

Restructuring, Impairment, and Related Charges (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2021
Restructuring and Related Activities [Abstract] |
Summary of details for charges recorded | Restructuring, impairment, and related charges, net for the year ended March 31, 2021 consisted of the following:
| Year Ended March 31, 2021
(In millions) | U.S. Pharmaceutical |  | International (1) |  | Medical-Surgical Solutions |  | Prescription Technology Solutions |  | Corporate (2) |  | Total
Severance and employee-related costs, net | $ | 10 |  |  | $ | 22 |  |  | $ | (1) |  |  | $ | 4 |  |  | $ | 69 |  |  | $ | 104 |
Exit and other-related costs (3) | 11 |  |  | 17 |  |  | 4 |  |  | — |  |  | 27 |  |  | 59 |
Asset impairments and accelerated depreciation | — |  |  | 46 |  |  | 1 |  |  | — |  |  | 9 |  |  | 56 |
Total | $ | 21 |  |  | $ | 85 |  |  | $ | 4 |  |  | $ | 4 |  |  | $ | 105 |  |  | $ | 219 |
(1)Primarily represents costs associated with the operating model and cost optimization efforts described above. (2)Represents costs associated with the operating model cost optimization efforts and the relocation of the Company’s headquarters described above in addition to various other initiatives. (3)Exit and other-related costs primarily include project consulting fees. Fiscal 2020 Restructuring, impairment, and related charges, net for the year ended March 31, 2020 consisted of the following:
| Year Ended March 31, 2020
(In millions) | U.S. Pharmaceutical (1) |  | International (2) |  | Medical-Surgical Solutions (3) |  | Prescription Technology Solutions |  | Corporate (4) |  | Total
Severance and employee-related costs, net | $ | 12 |  |  | $ | 2 |  |  | $ | 4 |  |  | $ | (1) |  |  | $ | 30 |  |  | $ | 47 |
Exit and other-related costs (5) | 1 |  |  | 13 |  |  | 19 |  |  | — |  |  | 46 |  |  | 79 |
Asset impairments and accelerated depreciation | 10 |  |  | 6 |  |  | 1 |  |  | — |  |  | 13 |  |  | 30 |
Total | $ | 23 |  |  | $ | 21 |  |  | $ | 24 |  |  | $ | (1) |  |  | $ | 89 |  |  | $ | 156 |
(1)Represents costs associated with dispositions and costs related to the relocation of the Company’s corporate headquarters described above. (2)Primarily represents costs associated with the operating model and cost optimization efforts described above. (3)Primarily represents costs associated with the growth initiative described above. (4)Represents costs associated with the growth initiative, operating model cost optimization efforts, and with the relocation of the Company’s corporate headquarters described above. (5)Exit and other-related costs primarily include project consulting fees. Fiscal 2019 Restructuring, impairment, and related charges, net for the year ended March 31, 2019 consisted of the following:
| Year Ended March 31, 2019
(In millions) | U.S. Pharmaceutical (1) |  | International (2) |  | Medical-Surgical Solutions (3) |  | Prescription Technology Solutions |  | Corporate (4) |  | Total
Severance and employee-related costs, net | $ | 46 |  |  | $ | 51 |  |  | $ | 18 |  |  | $ | 3 |  |  | $ | 36 |  |  | $ | 154 |
Exit and other-related costs (5) | 9 |  |  | 83 |  |  | 20 |  |  | — |  |  | 52 |  |  | 164
Asset impairments and accelerated depreciation | 6 |  |  | 24 |  |  | 3 |  |  | — |  |  | 1 |  |  | 34 |
Total | $ | 61 |  |  | $ | 158 |  |  | $ | 41 |  |  | $ | 3 |  |  | $ | 89 |  |  | $ | 352 |
(1)Represents costs associated with the operating model cost optimization efforts and growth initiative described above. (2)Primarily represents costs associated with the operating model cost optimization efforts and U.K. restructuring initiative focusing on underperforming retail pharmacy stores described above. (3)Primarily represents costs associated with the growth initiative described above. (4)Represents costs associated with operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above. (5)Exit and other-related costs primarily include lease and other contract exit costs associated with closures of facilities and retail pharmacy stores as well as project consulting fees. The following table summarizes the activity related to the restructuring liabilities associated with the Company’s restructuring initiatives for the years ended March 31, 2021 and 2020:
(In millions) | U.S. Pharmaceutical |  | International |  | Medical-Surgical Solutions |  | Prescription Technology Solutions |  | Corporate |  | Total
Balance, March 31, 2019 | $ | 35 |  |  | $ | 129 |  |  | $ | 26 |  |  | $ | 3 |  |  | $ | 44 |  |  | $ | 237 |
Restructuring, impairment, and related charges | 23 |  | 21 |  |  | 24 |  |  | (1) |  |  | 89 |  |  | 156
Non-cash charges | (10) |  |  | (6) |  |  | (1) |  |  | — |  |  | (13) |  |  | (30) |
Cash payments | (15) |  |  | (45) |  |  | (26) |  |  | (1) |  |  | (61) |  |  | (148) |
Other | (4) |  |  | (33) |  |  | (1) |  |  | — |  |  | (20) |  |  | (58) |
Balance, March 31, 2020 (1) | 29 |  |  | 66 |  |  | 22 |  |  | 1 |  |  | 39 |  |  | 157 |
Restructuring, impairment, and related charges | 21 |  |  | 85 |  |  | 4 |  |  | 4 |  |  | 105 |  |  | 219 |
Non-cash charges | — |  |  | (46) |  |  | (1) |  |  | — |  |  | (9) |  |  | (56) |
Cash payments | (31) |  |  | (31) |  |  | (21) |  |  | (1) |  |  | (75) |  |  | (159) |
Other | — |  |  | (8) |  |  | (1) |  |  | — |  |  | (1) |  |  | (10) |
Balance, March 31, 2021 (2) | $ | 19 |  |  | $ | 66 |  |  | $ | 3 |  |  | $ | 4 |  |  | $ | 59 |  |  | $ | 151 |
(1) As of March 31, 2020, the total reserve balance was $157 million of which $118 million was recorded in Other accrued liabilities and $39 million was recorded in Other non-current liabilities. (2) As of March 31, 2021, the total reserve balance was $151 million of which $99 million was recorded in Other accrued liabilities and $52 million was recorded in Other non-current liabilities.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration